Guthoff R, von Domarus D, Steinhorst U, Hallermann D
Klin Monbl Augenheilkd. 1986 Jun;188(6):576-83. doi: 10.1055/s-2008-1050719.
In 75% of the patients with malignant melanoma of the choroid useful vision can be retained by beta-radiation with ruthenium-106/rhodium. Tumors with a prominence of more than 6 mm should be treated only for very special reasons. There is a statistically proven correlation between the initial tumor volume and the occurrence of residual tissue volume. Histopathological investigations have shown that residuals of the tumor do not permit any conclusions concerning the dignity or vitality of tumor cells. The risk to life is not increased by the conservative procedure, and it may even be reduced.
在75%的脉络膜恶性黑色素瘤患者中，使用钌-106/铑进行β射线照射可保留有用视力。突出超过6毫米的肿瘤仅在非常特殊的情况下才应进行治疗。初始肿瘤体积与残留组织体积的发生之间存在统计学上已证实的相关性。组织病理学研究表明，肿瘤残留无法就肿瘤细胞的特性或活力得出任何结论。保守治疗方法不会增加生命风险，甚至可能降低风险。
